干扰素联合拉米夫定治疗乙型肝炎病毒相关性肾小球肾炎的效果分析

Effect of Interferon Combined with Lamivudine in the Treatment of Hepatitis B Virus Associated Glomerulonephritis

目的探究干扰素联合拉米夫定治疗乙型肝炎病毒相关性肾小球肾炎的效果。方法选择2016年6月-2018年8月该院收治的60例乙型肝炎病毒相关性肾小球肾炎患者,随机分为两组,每组30例,对照组接受拉米夫定治疗,观察组加用干扰素,比较两组治疗效果。结果(1)观察组治疗有效率93.3%,对照组治疗有效率73.3%,组间差异有统计学意义(χ^2=10.320,P<0.05)。(2)治疗后观察组白蛋白(35.9±5.3)g/L、血肌酐(61.2±10.2)umol/L、乙肝病毒脱氧核糖核酸(1.5±0.3)copies/mL、丙氨酸转氨酶(28.0±7.5)U/L以及24 h尿蛋白定量(1.6±0.4)g/24 h均显著优于对照组,组间差异有统计学意义(t=5.23、5.11、4.35、4.911、4.82,P<0.05)。(3)观察组不良反应几率10.0%,对照组不良反应几率30.0%,组间差异有统计学意义(χ^2=9.321,P<0.05)。结论干扰素联合拉米夫定治疗乙型肝炎病毒相关性肾小球肾炎的效果,值得临床推广。

Objective To investigate the effect of interferon combined with lamivudine in the treatment of hepatitis B virus-associated glomerulonephritis. Methods Sixty patients with hepatitis B virus-associated glomerulonephritis admitted to our hospital from June2016 to August 2018 were randomly divided into two groups, 30 cases in each group. The control group received lamivudine treatment. The observation group was supplemented with interferon and the effects of the two groups were compared. Results 1.The effective rate of treatment in the observation group was 93.3%, and the effective rate in the control group was 73.3%. The difference between the two groups was statistically significant(χ^2=10.320,P<0.05). 2.After treatment, the albumin was observed(35.9±5.3) g/L,serum creatinine(61.2 ±10.2) umol/L, hepatitis B virus deoxyribonucleic acid(1.5 ±0.3) copies/mL, alanine aminotransferase(28.0 ±7.5)U/L and 24 h urine protein quantitation(1.6±0.4) g/24 h was significantly better than the control group, the difference between the groups was statistically significant(t=5.23, 5.11, 4.35, 4.911, 4.82,P<0.05). 3.The adverse reaction rate of the observation group was10.0%, and the adverse reaction rate of the control group was 30.0%, the difference between the groups was statistically significant(χ^2=9.321,P <0.05). Conclusion The effect of interferon combined with lamivudine in the treatment of hepatitis B virus-associated glomerulonephritis is worthy of clinical promotion.